AKTX Key Statistics, Chart & Performance
The current stock price of AKTX is 0.2824 USD. In the past month the price decreased by -19.54%. In the past year, price decreased by -76.76%.
AKTX Latest News, Press Relases and Analysis
AKTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About AKTX
Company Profile
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in Tampa, Florida and currently employs 8 full-time employees. The company went IPO on 2014-01-31. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. The company is pursuing research on two additional novel payloads, such as PH5 and PH6. The company also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
Company Info
AKARI THERAPEUTICS PLC-ADR
401 East Jackson Street, Suite 3300
Tampa FLORIDA W1G 9RT US
CEO: Clive Richardson
Employees: 8
Phone: 19292747510
AKARI THERAPEUTICS PLC-ADR / AKTX FAQ
What does AKARI THERAPEUTICS PLC-ADR do?
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in Tampa, Florida and currently employs 8 full-time employees. The company went IPO on 2014-01-31. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. The company is pursuing research on two additional novel payloads, such as PH5 and PH6. The company also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
Can you provide the latest stock price for AKARI THERAPEUTICS PLC-ADR?
The current stock price of AKTX is 0.2824 USD. The price decreased by -1.74% in the last trading session.
Does AKTX stock pay dividends?
AKTX does not pay a dividend.
How is the ChartMill rating for AKARI THERAPEUTICS PLC-ADR?
AKTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the market cap for AKARI THERAPEUTICS PLC-ADR?
AKARI THERAPEUTICS PLC-ADR (AKTX) has a market capitalization of 9.21M USD. This makes AKTX a Nano Cap stock.
Can you provide the short interest for AKTX stock?
The outstanding short interest for AKARI THERAPEUTICS PLC-ADR (AKTX) is 232.33% of its float.
AKTX Technical Analysis
AKTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AKTX. AKTX has a bad profitability rating. Also its financial health evaluation is rather negative.
AKTX Financial Highlights
Over the last trailing twelve months AKTX reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS increased by 84.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.76% | ||
| ROE | -69.52% | ||
| Debt/Equity | 0.09 |
AKTX Forecast & Estimates
9 analysts have analysed AKTX and the average price target is 4.62 USD. This implies a price increase of 1537.38% is expected in the next year compared to the current price of 0.2824.